Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
Crossref DOI link: https://doi.org/10.1007/s12325-023-02568-0
Published Online: 2023-06-18
Published Print: 2023-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blauvelt, Andrew
Chiricozzi, Andrea
Ehst, Benjamin D.
Lebwohl, Mark G.
Funding for this research was provided by:
Sun Pharma
Text and Data Mining valid from 2023-06-18
Version of Record valid from 2023-06-18
Article History
Received: 7 April 2023
Accepted: 25 May 2023
First Online: 18 June 2023